Monocyte-derived IL-1 and IL-6 are differentially requi and neurotoxicity due to CAR T cells

Nature Medicine

24, 739-748

DOI: 10.1038/s41591-018-0036-4

Citation Report

#	Article	IF	Citations
1	Keeping the Engine Running: The Relevance and Predictive Value of Preclinical Models for CAR-T Cell Development. ILAR Journal, 2018, 59, 276-285.	1.8	5
2	Current development of chimeric antigen receptor T-cell therapy. Stem Cell Investigation, 2018, 5, 44-44.	1.3	26
4	Immunotherapy in non-Hodgkin lymphoma. Annals of Lymphoma, 0, 2, 9-9.	4.5	0
5	Cytokine release syndrome and neurotoxicity after <scp>CD</scp>19 chimeric antigen receptorâ€modified (<scp>CAR</scp>â€) T cell therapy. British Journal of Haematology, 2018, 183, 364-374.	1.2	131
6	Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2018, 11, 130.	6.9	25
7	The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochemical Society Transactions, 2018, 46, 1449-1462.	1.6	88
8	Adrenaline fuels a cytokine storm during immunotherapy. Nature, 2018, 564, 194-196.	13.7	18
9	The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunology Research, 2018, 6, 1445-1452.	1.6	132
10	Disruption of aÂself-amplifying catecholamine loop reduces cytokine release syndrome. Nature, 2018, 564, 273-277.	13.7	193
11	Cytokine release syndrome: grading, modeling, and new therapy. Journal of Hematology and Oncology, 2018, 11, 121.	6.9	99
12	Genetically modified immune cells for cancer immunotherapy. Science China Life Sciences, 2018, 61, 1277-1279.	2.3	3
13	Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nature Reviews Immunology, 2018, 18, 773-789.	10.6	662
14	Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. CNS Drugs, 2018, 32, 1091-1101.	2.7	175
15	CAR-T immunotherapy: how will it change treatment for acute lymphoblastic leukemia and beyond?. Expert Opinion on Orphan Drugs, 2018, 6, 563-566.	0.5	4
16	In vivo generation of human <scp>CD</scp> 19â€•<scp>CAR</scp> T cells results in Bâ€cell depletion and signs of cytokine release syndrome. EMBO Molecular Medicine, 2018, 10, .	3.3	105
17	No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Hematology American Society of Hematology Education Program, 2018, 2018, 25-34.	0.9	29
18	No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Advances, 2018, 2, 3393-3403.	2.5	41
19	Modeling cytokine release syndrome. Nature Medicine, 2018, 24, 705-706.	15.2	18

#	Article	IF	Citations
20	Interleukin (IL)-6: A good kid hanging out with bad friends (and why sauna is good for health). Brain, Behavior, and Immunity, 2018, 73, 1-2.	2.0	20
21	Calming the cytokine storm. Nature Reviews Immunology, 2018, 18, 417-417.	10.6	16
22	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology, 2019, 16, 45-63.	12.5	178
23	Host conditioning with IL-1Î² improves the antitumor function of adoptively transferred T cells. Journal of Experimental Medicine, 2019, 216, 2619-2634.	4.2	51
24	Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. Bone Marrow Transplantation, 2019, 54, 780-784.	1.3	52
25	Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. Expert Opinion on Biological Therapy, 2019, 19, 1157-1164.	1.4	14
26	Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date . OncoTargets and Therapy, 2019, Volume 12, 4543-4554.	1.0	6
27	Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity. , 2019, 7, 188.		12
28	Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 393-419.	2.7	45
29	Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment. Current Treatment Options in Neurology, 2019, 21, 40.	0.7	65
30	Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Frontiers in Immunology, 2019, 10, 1613.	2.2	70
31	IFN-Î³ and TNF-Î± aggravate endothelial damage caused by CD123-targeted CAR T cell . OncoTargets and Therapy, 2019, Volume 12, 4907-4925.	1.0	28
32	Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy, 2019, 11, 851-857.	1.0	48
33	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood, 2019, 134, 860-866.	0.6	178
34	Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities. Cancer Letters, 2019, 462, 23-32.	3.2	87
35	Cellular therapy: Immuneâ€related complications. Immunological Reviews, 2019, 290, 114-126.	2.8	55
36	CAR T cells for brain tumors: Lessons learned and road ahead. Immunological Reviews, 2019, 290, 60-84.	2.8	151
37	Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells. Biomaterials, 2019, 219, 119401.	5.7	51

#	Article	IF	Citations
38	The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Science Translational Medicine, 2019, 11, .	5.8	326
39	Immune-Based Therapies in Acute Leukemia. Trends in Cancer, 2019, 5, 604-618.	3.8	32
40	Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. European Journal of Cancer, 2019, 122, 22-41.	1.3	7
41	Advances in Engineering Cells for Cancer Immunotherapy. Theranostics, 2019, 9, 7889-7905.	4.6	44
42	CAR-T â€œthe living drugsâ€, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. Journal of Hematology and Oncology, 2019, 12, 113.	6.9	69
44	Application Of Adoptive Immunotherapy In Ovarian Cancer . OncoTargets and Therapy, 2019, Volume 12, 7975-7991.	1.0	4
45	The Endless Saga of Monocyte Diversity. Frontiers in Immunology, 2019, 10, 1786.	2.2	67
46	Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies. Journal of Bone and Mineral Research, 2019, 34, 1780-1788.	3.1	12
47	CD3 bispecific antibodyâ€“induced cytokine release is dispensable for cytotoxic T cell activity. Science Translational Medicine, 2019, 11, .	5.8	117
48	Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction. Bone Marrow Transplantation, 2019, 54, 759-764.	1.3	18
49	Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine, 2019, 25, 1341-1355.	15.2	400
50	Engineered T Cell Therapy for Cancer in the Clinic. Frontiers in Immunology, 2019, 10, 2250.	2.2	267
51	Genetically engineered T cells for cancer immunotherapy. Signal Transduction and Targeted Therapy, 2019, 4, 35.	7.1	153
52	T cell engineering for adoptive T cell therapy: safety and receptor avidity. Cancer Immunology, Immunotherapy, 2019, 68, 1701-1712.	2.0	41
53	Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies. Frontiers in Immunology, 2019, 10, 1876.	2.2	35
54	Î³-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood, 2019, 134, 1585-1597.	0.6	209
55	Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. British Journal of Cancer, 2019, 121, 837-845.	2.9	124
57	B-cell depleting immunotherapies: therapeutic opportunities and toxicities. Expert Review of Clinical Immunology, 2019, 15, 497-509.	1.3	3

#	Article	IF	Citations
58	The Immunology of Macrophage Activation Syndrome. Frontiers in Immunology, 2019, 10, 119.	2.2	448
59	Targeting the A₃ adenosine receptor to treat cytokine release syndrome in cancer immunotherapy . Drug Design, Development and Therapy, 2019, Volume 13, 491-497.	2.0	28
60	Specific sequences of infectious challenge lead to secondary hemophagocytic lymphohistiocytosis-like disease in mice. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2200-2209.	3.3	40
61	Critical Care Management of Chimeric Antigen Receptor T Cellâ€"related Toxicity. Be Aware and Prepared. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 20-23.	2.5	34
62	CARs of the future. American Journal of Hematology, 2019, 94, S55-S58.	2.0	10
63	Clinical chimeric antigen receptorâ€T cell therapy: a new and promising treatment modality for glioblastoma. Clinical and Translational Immunology, 2019, 8, e1050.	1.7	33
64	Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. Nature Communications, 2019, 10, 2681.	5.8	69
65	Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Review of Clinical Immunology, 2019, 15, 813-822.	1.3	221
66	Target selection for CAR-T therapy. Journal of Hematology and Oncology, 2019, 12, 62.	6.9	118
67	Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care. , 2019, , 1-13.		1
68	Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Frontiers in Immunology, 2019, 10, 990.	2.2	86
70	Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines. Frontiers in Immunology, 2019, 10, 1093.	2.2	84
71	Managing the toxicities of CAR Tâ€cell therapy. Hematological Oncology, 2019, 37, 48-52.	0.8	214
72	Glial injury in neurotoxicity after pediatric CD19â€directed chimeric antigen receptor T cell therapy. Annals of Neurology, 2019, 86, 42-54.	2.8	124
73	The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 433-444.	1.8	200
74	The emerging roles of inflammasomeâ€dependent cytokines in cancer development. EMBO Reports, 2019, 20, .	2.0	77
75	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)â€"an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	1.3	86
76	A safe and potent anti-CD19 CAR T cell therapy. Nature Medicine, 2019, 25, 947-953.	15.2	314

#	Article	IF	Citations
77	Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel . Cancer Management and Research, 2019, Volume 11, 2393-2404.	0.9	14
78	Suppressive effects of sunitinib on a TLR activation-induced cytokine storm. European Journal of Pharmacology, 2019, 854, 347-353.	1.7	20
79	Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity, 2019, 50, 778-795.	6.6	639
80	Targeting Interleukin-6 Signaling in Clinic. Immunity, 2019, 50, 1007-1023.	6.6	570
81	Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor Tâ€Cell Therapy. Clinical and Translational Science, 2019, 12, 343-349.	1.5	50
82	CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Therapeutic Advances in Hematology, 2019, 10, 204062071984158.	1.1	160
83	Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice. Journal of Oncology Pharmacy Practice, 2019, 25, 1217-1225.	0.5	12
84	Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. International Journal of Molecular Sciences, 2019, 20, 1283.	1.8	296
85	PlcÎ32/Tmem178 dependent pathway in myeloid cells modulates the pathogenesis of cytokine storm syndrome. Journal of Autoimmunity, 2019, 100, 62-74.	3.0	25
86	Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain, 2019, 142, 1334-1348.	3.7	166
87	Engineering advanced cancer therapies with synthetic biology. Nature Reviews Cancer, 2019, 19, 187-195.	12.8	46
88	Interferon-Î3 upregulates Î”42PD1 expression on human monocytes via the PI3K/AKT pathway. Immunobiology, 2019, 224, 388-396.	0.8	4
89	Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. Gastroenterology, 2019, 156, 1862-1876.e9.	0.6	92
90	The Emergence of Universal Immune Receptor T Cell Therapy for Cancer. Frontiers in Oncology, 2019, 9, 176.	1.3	64
91	Chimeric Antigen Receptorâ€“Engineered T Cell Therapy in Lymphoma. Current Oncology Reports, 2019, 21, 38.	1.8	20
92	Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy . Therapeutics and Clinical Risk Management, 2019, Volume 15, 323-335.	0.9	110
93	Development and Significance of Mouse Models in Lymphoma Research. Current Hematologic Malignancy Reports, 2019, 14, 119-126.	1.2	2
94	The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy. Trends in Immunology, 2019, 40, 292-309.	2.9	61

#	Article	IF	Citations
95	Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity. International Immunopharmacology, 2019, 70, 498-503.	1.7	21
96	Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies. Trends in Immunology, 2019, 40, 274-278.	2.9	7
97	Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy. Transfusion Medicine and Hemotherapy, 2019, 46, 15-24.	0.7	107
98	CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 328-335.	0.8	31
99	Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Review of Hematology, 2019, 12, 195-205.	1.0	63
100	Cellular immunotherapy for acute myeloid leukemia: How specific should it be?. Blood Reviews, 2019, 35, 18-31.	2.8	23
101	Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. Journal of Hematology and Oncology, 2019, 12, 17.	6.9	80
102	Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2019, 12, 15.	6.9	38
103	CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions. Journal of the National Cancer Institute, 2019, 111, 646-654.	3.0	126
104	Granulocyteâ€“macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. Journal of Biological Chemistry, 2019, 294, 5430-5437.	1.6	114
105	Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood, 2019, 133, 2212-2221.	0.6	207
106	Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia, 2019, 33, 2195-2207.	3.3	56
107	Monocyte heterogeneity and functions in cancer. Journal of Leukocyte Biology, 2019, 106, 309-322.	1.5	330
108	Toxicities of CD19 CARâ€¶ cell immunotherapy. American Journal of Hematology, 2019, 94, S42-S49.	2.0	102
109	Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1092-1098.	2.0	79
110	Pharmacologic control of CAR-T cell function using dasatinib. Blood Advances, 2019, 3, 711-717.	2.5	143
112	Cytokine release syndrome: a primer for generalists. Adverse Drug Reaction Bulletin, 2019, 319, 1235-1238.	0.6	0
113	Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review. Future Oncology, 2019, 15, 4235-4246.	1.1	5

#	Article	IF	Citations
114	The CNS can be a safe space for CARs. Blood, 2019, 134, 845-846.	0.6	3
115	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Advances, 2019, 3, 1970-1980.	2.5	164
117	Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). Journal of the American College of Cardiology, 2019, 74, 3099-3108.	1.2	225
118	Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma. Cancers, 2019, 11, 2024.	1.7	12
119	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. Cancer Cell, 2019, 36, 613-629.e7.	7.7	99
120	Can Bioactive Lipids Augment Anti-cancer Action of Immunotherapy and Prevent Cytokine Storm?. Archives of Medical Research, 2019, 50, 342-349.	1.5	23
121	Cytokine Release Syndrome: Current Perspectives . ImmunoTargets and Therapy, 2019, Volume 8, 43-52.	2.7	116
122	Management of T-Cell Engaging Immunotherapy Complications. Cancer Journal (Sudbury, Mass), 2019, 25, 223-230.	1.0	15
123	Current status and hurdles for CAR-T cell immune therapy. Blood Science, 2019, 1, 148-155.	0.4	5
124	CAR T Cell Toxicity: Current Management and Future Directions. HemaSphere, 2019, 3, e186.	1.2	121
125	In the Eye of the Storm: Immuneâ€mediated Toxicities Associated With CARâ€T Cell Therapy. HemaSphere, 2019, 3, e191.	1.2	80
126	Next Generation of Cancer Treatments: Chimeric Antigen Receptor T-Cell Therapy and Its Related Toxicities: A Review for Perioperative Physicians. Anesthesia and Analgesia, 2019, 129, 434-441.	1.1	11
127	What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?. Journal of Pediatric Hematology/Oncology, 2019, 41, 337-344.	0.3	16
128	Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. Drugs in Context, 2019, 8, 1-14.	1.0	29
129	Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. EBioMedicine, 2019, 39, 173-181.	2.7	47
130	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation, 2019, 25, 625-638.	2.0	1,741
131	Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. BioDrugs, 2019, 33, 45-60.	2.2	61
132	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85

#	Article	IF	Citations
133	Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation, 2019, 54, 969-972.	1.3	13
134	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Clinical Cancer Research, 2019, 25, 2042-2048.	3.2	77
135	Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Reviews, 2019, 34, 45-55.	2.8	570
136	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood, 2019, 133, 697-709.	0.6	408
137	Adoptive cellular therapies: the current landscape. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 449-461.	1.4	261
138	Safety and Tolerability of Adoptive Cell Therapy in Cancer. Drug Safety, 2019, 42, 315-334.	1.4	57
139	T-cells â€œÃ la CAR-T(e)â€•â€“ Genetically engineering T-cell response against cancer. Advanced Drug Delivery Reviews, 2019, 141, 23-40.	6.6	17
140	Construction and functional characterization of a fully human antiâ€CD19 chimeric antigen receptor (huCAR)â€expressing primary human TÂcells. Journal of Cellular Physiology, 2019, 234, 9207-9215.	2.0	37
141	Emerging Cellular Therapies for Cancer. Annual Review of Immunology, 2019, 37, 145-171.	9.5	263
142	A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia. Bone Marrow Transplantation, 2019, 54, 1208-1217.	1.3	37
143	Towards the development of human immune-system-on-a-chip platforms. Drug Discovery Today, 2019, 24, 517-525.	3.2	75
144	Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 1-6.	0.6	12
145	Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. Bone Marrow Transplantation, 2020, 55, 1821-1823.	1.3	1
146	Human macrophages and innate lymphoid cells: Tissue-resident innate immunity in humanized mice. Biochemical Pharmacology, 2020, 174, 113672.	2.0	10
147	Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. Regenerative Engineering and Translational Medicine, 2020, 6, 29-49.	1.6	16
149	Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. CNS Drugs, 2020, 34, 127-145.	2.7	26
152	Current challenges and emerging opportunities of CAR-T cell therapies. Journal of Controlled Release, 2020, 319, 246-261.	4.8	78
153	Recent Advancements and Applications of Human Immune System Mice in Preclinical Immuno-Oncology. Toxicologic Pathology, 2020, 48, 302-316.	0.9	17

#	Article	IF	Citations
154	Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology, 2020, 17, 147-167.	12.5	786
155	Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. Current Opinion in Hematology, 2020, 27, 41-48.	1.2	14
156	scFv Cloning, Vectors, and CAR-T Production in Laboratory for Preclinical Applications. , 2020, , 25-49.		0
157	Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. Critical Care Medicine, 2020, 48, 10-21.	0.4	42
158	Challenges and Opportunities to Improve CAR T-Cell Therapy. , 2020, , 63-80.		1
159	CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges. Briefings in Functional Genomics, 2020, 19, 183-190.	1.3	4
160	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica, 2020, 105, 297-316.	1.7	230
161	Role of CAR-T cell therapy in B-cell acute lymphoblastic leukemia. Memo - Magazine of European Medical Oncology, 2020, 13, 36-42.	0.3	3
162	Management of Cytokine Release Syndrome. , 2020, , 45-64.		1
163	CAR T-Cell Therapy for CNS Malignancies. , 2020, , 165-198.		0
164	Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu. Shock, 2020, 54, 438-450.	1.0	19
165	Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study. Annals of Translational Medicine, 2020, 8, 1048-1048.	0.7	5
166	Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. Frontiers in Oncology, 2020, 10, 1594.	1.3	46
167	Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Clinical Cancer Research, 2020, 26, 6299-6309.	3.2	49
168	A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. Neurologic Clinics, 2020, 38, 953-963.	0.8	14
169	Iatrogenic Neuropathology of Systemic Therapies. Surgical Pathology Clinics, 2020, 13, 331-342.	0.7	4
171	The multifaceted role of plasminogen in inflammation. Cellular Signalling, 2020, 75, 109761.	1.7	68
172	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 4898-4911.	2.5	238

#	Article	IF	Citations
173	Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia. Medical Oncology, 2020, 37, 100.	1.2	32
174	Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respiratory Medicine,the, 2020, 8, 1233-1244.	5.2	661
175	Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia. Translational Oncology, 2020, 13, 100838.	1.7	15
176	Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nature Medicine, 2020, 26, 1878-1887.	15.2	321
177	CAR T cell therapy. Immunological Medicine, 2021, 44, 69-73.	1.4	4
178	Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. Journal of Infection, 2020, 81, e11-e17.	1.7	102
179	Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clinical Cancer Research, 2020, 26, 4823-4831.	3.2	47
180	Macrophage, the potential key mediator in CAR-T related CRS. Experimental Hematology and Oncology, 2020, 9, 15.	2.0	54
181	THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells. Cancer Cell, 2020, 37, 216-225.e6.	7.7	89
182	Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kineticâ€Pharmacodynamic Modeling Approaches. Journal of Clinical Pharmacology, 2020, 60, S147-S159.	1.0	28
183	Using single-cell analysis to predict CAR T cell outcomes. Nature Medicine, 2020, 26, 1813-1814.	15.2	2
184	Autologous nonâ€human primate model for safety assessment of piggyBac transposonâ€mediated chimeric antigen receptor T cells on granulocyteâ€“macrophage colonyâ€stimulating factor receptor. Clinical and Translational Immunology, 2020, 9, e1207.	1.7	6
185	A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma. Frontiers of Medicine, 2020, 14, 711-725.	1.5	8
186	Cytokine Storm. New England Journal of Medicine, 2020, 383, 2255-2273.	13.9	1,911
187	Natural killer cells in cancer biology and therapy. Molecular Cancer, 2020, 19, 120.	7.9	344
188	Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nature Communications, 2020, 11, 3924.	5.8	180
189	Hematopoietic stem cell transplantation and chimeric antigen receptor TÂcell for relapsed or refractory diffuse large B-cell lymphoma. Immunotherapy, 2020, 12, 997-1006.	1.0	17
190	Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy . Infection and Drug Resistance, 2020, Volume 13, 2485-2493.	1.1	93

#	Article	IF	Citations
191	Acute life-threatening toxicity from CAR T-cell therapy. Intensive Care Medicine, 2020, 46, 1723-1726.	3.9	14
192	CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. Frontiers in Oncology, 2020, 10, 1243.	1.3	63
193	The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies. Cancers, 2020, 12, 2030.	1.7	19
194	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduction and Targeted Therapy, 2020, 5, 134.	7.1	84
195	Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma. Pancreatology, 2020, 20, 394-408.	0.5	10
196	Improving CAR T-cells: The next generation. Seminars in Hematology, 2020, 57, 115-121.	1.8	13
197	Inflammasome activation by<scp>Pseudomonas aeruginosa'</scp>s<scp>ExlA</scp>poreâ€forming toxin is detrimental for the host. Cellular Microbiology, 2020, 22, e13251.	1.1	11
198	Overcoming key challenges in cancer immunotherapy with engineered T cells. Current Opinion in Oncology, 2020, 32, 398-407.	1.1	9
199	The Perfect Storm: COVID-19 Health Disparities in US Blacks. Journal of Racial and Ethnic Health Disparities, 2021, 8, 1153-1160.	1.8	48
200	The many faces of the anti-COVID immune response. Journal of Experimental Medicine, 2020, 217, .	4.2	437
201	A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies. Translational Cancer Research, 2020, 9, 5655-5662.	0.4	1
202	Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy. Molecular Therapy, 2020, 28, 2252-2270.	3.7	29
203	Mapping and targeting of the leukemic microenvironment. Journal of Experimental Medicine, 2020, 217, .	4.2	29
204	Systemic Complications of COVID-19. Critical Care Nursing Quarterly, 2020, 43, 390-399.	0.4	20
205	Neurological Aspects of SARS-CoV-2 Infection: Mechanisms and Manifestations. Frontiers in Neurology, 2020, 11, 1039.	1.1	66
206	Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. Journal of Allergy and Clinical Immunology, 2020, 146, 940-948.	1.5	78
207	BCMA-targeted immunotherapy for multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 125.	6.9	108
208	Emerging immunotherapies in multiple myeloma. BMJ, The, 2020, 370, m3176.	3.0	62

#	Article	IF	Citations
209	Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 3943-3951.	2.5	69
210	The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. Cell Communication and Signaling, 2020, 18, 134.	2.7	28
211	Human Autoinflammatory Diseases Mediated by NLRP3-, Pyrin-, NLRP1-, and NLRC4-Inflammasome Dysregulation Updates on Diagnosis, Treatment, and the Respective Roles of IL-1 and IL-18. Frontiers in Immunology, 2020, 11, 1840.	2.2	67
212	Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Frontiers in Immunology, 2020, 11, 1973.	2.2	148
213	Podoplanin as an Attractive Target of CAR T Cell Therapy. Cells, 2020, 9, 1971.	1.8	8
214	Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. OncoImmunology, 2020, 9, 1806009.	2.1	22
215	Externally-Controlled Systems for Immunotherapy: From Bench to Bedside. Frontiers in Immunology, 2020, 11, 2044.	2.2	18
216	<scp>SARSâ€CoV</scp>â€2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities. IUBMB Life, 2020, 72, 2313-2330.	1.5	10
217	Humanized Rodent Models for Cancer Research. Frontiers in Oncology, 2020, 10, 1696.	1.3	68
218	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. , 2020, 2, e0178.		34
219	New targets and technologies for CAR-T cells. Current Opinion in Oncology, 2020, 32, 510-517.	1.1	12
220	Overhauling CAR T Cells to Improve Efficacy, Safety and Cost. Cancers, 2020, 12, 2360.	1.7	9
221	Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome. Journal of Clinical Immunology, 2020, 40, 1082-1092.	2.0	48
222	IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22351-22356.	3.3	215
223	Differential clusterization of soluble and extracellular vesicle-associated cytokines in myocardial infarction. Scientific Reports, 2020, 10, 21114.	1.6	8
224	Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. Frontiers in Immunology, 2020, 11, 620312.	2.2	21
225	Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. Frontiers in Oncology, 2020, 10, 599933.	1.3	15
226	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Review of Clinical Immunology, 2020, 16, 1185-1204.	1.3	23

#	Article	IF	Citations
227	ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis. Cytokine, 2020, 136, 155256.	1.4	26
228	Human Immune System Mice With Autologous Tumor for Modeling Cancer Immunotherapies. Frontiers in Immunology, 2020, 11, 591669.	2.2	6
229	Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. Haematologica, 2020, 106, 173-184.	1.7	25
230	Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmunity Reviews, 2020, 19, 102567.	2.5	521
231	Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatology, The, 2020, 2, e358-e367.	2.2	197
232	Biomarkers in individualized management of chimeric antigen receptor T cell therapy. Biomarker Research, 2020, 8, 13.	2.8	23
234	Advances in CAR T Therapy for Hematologic Malignancies. Pharmacotherapy, 2020, 40, 741-755.	1.2	11
235	The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. , 2020, 8, e000930.		77
236	Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?. , 2020, 8, e000742.		15
237	A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity. Molecular Therapy - Oncolytics, 2020, 17, 278-292.	2.0	9
238	Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell, 2020, 181, 1036-1045.e9.	13.5	3,572
239	Intrathecal chemotherapy for management of steroid-refractory CAR T-cellâ€“associated neurotoxicity syndrome. Blood Advances, 2020, 4, 2119-2122.	2.5	32
241	The amount of cytokine-release defines different shades of Sars-Cov2 infection. Experimental Biology and Medicine, 2020, 245, 970-976.	1.1	32
242	CAR T-cell immunotherapy of B-cell malignancy: the story so far. , 2020, 8, 251513552092716.	1.4	30
243	Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. EBioMedicine, 2020, 56, 102822.	2.7	17
244	Development of bispecific antibodies in China: overview and prospects. Antibody Therapeutics, 2020, 3, 126-145.	1.2	20
245	Targeting the NLRP3 Inflammasome in Severe COVID-19. Frontiers in Immunology, 2020, 11, 1518.	2.2	329
246	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatology, The, 2020, 2, e474-e484.	2.2	772

#	Article	IF	Citations
247	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Frontiers in Immunology, 2020, 11, 888.	2.2	45
248	A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. International Journal of Molecular Sciences, 2020, 21, 3886.	1.8	23
249	Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. , 2020, 8, e000621.		29
250	Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomarker Research, 2020, 8, 18.	2.8	51
251	Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatology, The, 2020, 2, e393-e400.	2.2	526
252	Neurotoxicityâ€"CAR T-cell therapy: what the neurologist needs to know. Practical Neurology, 2020, 20, 285-293.	0.5	30
253	Senolytic CAR T cells reverse senescence-associated pathologies. Nature, 2020, 583, 127-132.	13.7	483
254	A Comprehensive Review of Tocilizumab in COVIDâ€19 Acute Respiratory Distress Syndrome. Journal of Clinical Pharmacology, 2020, 60, 1131-1146.	1.0	65
255	IL6 Fuels Durable Memory for Th17 Cellâ€"Mediated Responses to Tumors. Cancer Research, 2020, 80, 3920-3932.	0.4	16
256	Engineering Cytoplasmic Signaling of CD28Î¶ CARs for Improved Therapeutic Functions. Frontiers in Immunology, 2020, 11, 1046.	2.2	9
257	Chimeric antigen receptor Tâ€cell therapies: Optimising the dose. British Journal of Clinical Pharmacology, 2020, 86, 1678-1689.	1.1	25
258	Adult and Cord Blood-Derived High-Affinity gB-CAR-T Cells Effectively React Against Human Cytomegalovirus Infections. Human Gene Therapy, 2020, 31, 423-439.	1.4	23
259	Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Molecular Therapy, 2020, 28, 1251-1262.	3.7	89
260	A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy. Frontiers in Oncology, 2020, 10, 262.	1.3	48
261	Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1575-1582.	1.2	28
262	Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer. Cancers, 2020, 12, 842.	1.7	21
263	Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. International Journal of Antimicrobial Agents, 2020, 55, 105954.	1.1	1,442
264	CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. Frontiers in Immunology, 2020, 11, 99.	2.2	42

#	Article	IF	Citations
265	Neurological Complications of CAR T Cell Therapy. Current Oncology Reports, 2020, 22, 83.	1.8	16
266	Advances in Supportive Care for Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2020, 15, 276-293.	1.2	8
267	Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors. Journal of Leukocyte Biology, 2020, 108, 1067-1079.	1.5	50
268	Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a. Biomedicine and Pharmacotherapy, 2020, 129, 110436.	2.5	25
269	Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications. International Journal of Molecular Sciences, 2020, 21, 4782.	1.8	68
271	High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. Science Advances, 2020, 6, eaba5542.	4.7	48
272	Clinical efficacy of anakinra to mitigate CAR T-cell therapyâ€“associated toxicity in large B-cell lymphoma. Blood Advances, 2020, 4, 3123-3127.	2.5	115
273	SARS-COV-2 and eye immunity: the lesson was learned but we are not done yet. Brainstorming on possible pathophysiology inspired by ocular models. International Ophthalmology, 2020, 40, 1879-1883.	0.6	12
274	Understanding Normal and Malignant Human Hematopoiesis Using Next-Generation Humanized Mice. Trends in Immunology, 2020, 41, 706-720.	2.9	23
276	Toxicities of novel therapies for hematologic malignancies. Expert Review of Hematology, 2020, 13, 241-257.	1.0	2
277	Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics, 2020, 12, 194.	2.0	40
278	Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics. Journal of Immunotoxicology, 2020, 17, 67-85.	0.9	30
279	Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opinion on Biological Therapy, 2020, 20, 653-664.	1.4	39
280	Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia. Chinese Medical Journal, 2020, 133, 474-482.	0.9	9
281	A novel role of NLRP3-generated IL-1Î² in the acute-chronic transition of peripheral lipopolysaccharide-elicited neuroinflammation: implications for sepsis-associated neurodegeneration. Journal of Neuroinflammation, 2020, 17, 64.	3.1	60
282	Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy. Frontiers in Oncology, 2020, 9, 1529.	1.3	23
283	Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma. Frontiers in Oncology, 2020, 10, 59.	1.3	24
284	Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. Biology of Blood and Marrow Transplantation, 2020, 26, 1071-1076.	2.0	63

#	Article	IF	Citations
285	CAR T-Cell-Associated Neurotoxicity. Critical Care Nursing Quarterly, 2020, 43, 191-204.	0.4	28
286	CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia, 2020, 34, 3228-3241.	3.3	27
287	Chimeric antigen receptor T-cell therapy for multiple myeloma. International Journal of Hematology, 2020, 111, 530-534.	0.7	5
288	Gasdermin Eâ€“mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Science Immunology, 2020, 5, .	5.6	314
289	Glypican-3â€“Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunology Research, 2020, 8, 309-320.	1.6	134
290	Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. Pediatric Neurology, 2020, 107, 7-15.	1.0	2
291	Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062071989989.	1.1	31
292	GP130 Cytokines in Breast Cancer and Bone. Cancers, 2020, 12, 326.	1.7	29
293	Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment. Clinical and Translational Oncology, 2020, 22, 1923-1937.	1.2	14
294	The Emerging Landscape of Immune Cell Therapies. Cell, 2020, 181, 46-62.	13.5	247
295	Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?. Journal of Autoimmunity, 2020, 111, 102452.	3.0	606
296	Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS). Bone Marrow Transplantation, 2020, 55, 2052-2055.	1.3	5
297	Advances in living cell-based anticancer therapeutics. Biomaterials Science, 2020, 8, 2344-2365.	2.6	22
298	Toxicity Induced by a Bispecific T Cellâ€“Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice. Journal of Immunology, 2020, 204, 2973-2983.	0.4	14
299	Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment. Clinical and Translational Radiation Oncology, 2020, 23, 27-29.	0.9	50
300	Dissecting the Tumorâ€“Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. Clinical Cancer Research, 2020, 26, 3505-3513.	3.2	18
301	The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells. PLoS ONE, 2020, 15, e0231896.	1.1	11
302	C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. , 2020, 8, e000234.		56

#	Article	IF	Citations
303	Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy. Blood, 2020, 135, 668-679.	0.6	7
304	Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events. Cancer Research, 2020, 80, 91-101.	0.4	54
305	Myeloid cellâ€“targeted miR-146a mimic inhibits NF-ÎºBâ€“driven inflammation and leukemia progression in vivo. Blood, 2020, 135, 167-180.	0.6	88
306	MicroRNA immunomodulating therapeutics. Blood, 2020, 135, 155-156.	0.6	5
307	Chimeric antigen receptorâ€“T cells with cytokine neutralizing capacity. Blood Advances, 2020, 4, 1419-1431.	2.5	27
308	First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Advances, 2020, 4, 1307-1310.	2.5	215
309	Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2020, 13, 30.	6.9	187
310	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 29.	6.9	146
311	Chimeric antigen receptor Tâ€cell therapy toxicities. British Journal of Clinical Pharmacology, 2021, 87, 2414-2424.	1.1	19
312	Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. Blood Reviews, 2021, 45, 100707.	2.8	137
313	Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies. Molecular Therapy, 2021, 29, 433-441.	3.7	22
314	Cytokine storm syndrome in coronavirus disease 2019: A narrative review. Journal of Internal Medicine, 2021, 289, 147-161.	2.7	177
315	Immune effector cellâ€“associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro-Oncology, 2021, 23, 112-121.	0.6	53
316	Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica, 2021, 106, 1504-1506.	1.7	14
317	Toward Better Understanding and Management of CAR-T Cellâ€“Associated Toxicity. Annual Review of Medicine, 2021, 72, 365-382.	5.0	34
318	Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations. Annals of Pharmacotherapy, 2021, 55, 466-479.	0.9	6
319	IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. Journal of Allergy and Clinical Immunology, 2021, 147, 72-80.e8.	1.5	166
320	Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm. Cancer Immunology, Immunotherapy, 2021, 70, 1127-1142.	2.0	7

#	Article	IF	Citations
321	Improving safety of cancer immunotherapy via delivery technology. Biomaterials, 2021, 265, 120407.	5.7	22
322	Filgrastim associations with <scp>CAR</scp> Tâ€cell therapy. International Journal of Cancer, 2021, 148, 1192-1196.	2.3	21
323	Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplantation, 2021, 56, 552-566.	1.3	113
324	Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. Neuro-Oncology Practice, 2021, 8, 259-265.	1.0	3
325	Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies. Critical Care Clinics, 2021, 37, 47-67.	1.0	5
326	Combining Antivirals and Immunomodulators to Fight COVID-19. Trends in Immunology, 2021, 42, 31-44.	2.9	46
327	IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia, 2021, 35, 1380-1391.	3.3	26
328	Kidney involvement in COVIDâ€19ÂÂand its treatments. Journal of Medical Virology, 2021, 93, 1387-1395.	2.5	68
329	Prolonged neurotoxicity in a lymphoma patient after CD19â€directed CAR Tâ€cell therapy: A case report and brief review of the literature. Advances in Cell and Gene Therapy, 2021, 4, e104.	0.6	1
330	Considerations for designing preclinical cancer immune nanomedicine studies. Nature Nanotechnology, 2021, 16, 6-15.	15.6	77
331	IL-6 in inflammation, autoimmunity and cancer. International Immunology, 2021, 33, 127-148.	1.8	500
332	Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. Theranostics, 2021, 11, 1016-1030.	4.6	149
333	Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients. Cancer Cell, 2021, 39, 276-283.e3.	7.7	54
334	Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals of Oncology, 2021, 32, 34-48.	0.6	231
335	Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy. Journal of Controlled Release, 2021, 329, 1023-1036.	4.8	18
336	Photoswitchable CAR-T Cell Function InÂVitro and InÂVivo via a Cleavable Mediator. Cell Chemical Biology, 2021, 28, 60-69.e7.	2.5	17
337	Laboratory Biomarkers in the Management of Patients With COVID-19. American Journal of Clinical Pathology, 2021, 155, 333-342.	0.4	18
338	T cell immunobiology and cytokine storm of COVIDâ€19. Scandinavian Journal of Immunology, 2021, 93, e12989.	1.3	77

#	Article	IF	Citations
339	Neurological updates: neurological complications of CAR-T therapy. Journal of Neurology, 2021, 268, 1544-1554.	1.8	37
340	Cytokine syndromes associated with hematopoietic cellular therapy. Advances in Cell and Gene Therapy, 2021, 4, .	0.6	1
341	Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. British Journal of Cancer, 2021, 124, 359-367.	2.9	590
342	Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. OMICS A Journal of Integrative Biology, 2021, 25, 13-22.	1.0	16
343	Angiotensinâ€converting enzyme as a new immunologic target for the new SARSâ€CoVâ€2. Immunology and Cell Biology, 2021, 99, 192-205.	1.0	5
344	Mouse Models of the Humanized Immune System. , 2021, , 725-742.		0
345	CAR T Toxicity Management: Cytokine Release Syndrome and Neurotoxicity. , 2021, , 915-928.		0
346	Direct control of CAR T cells through small molecule-regulated antibodies. Nature Communications, 2021, 12, 710.	5.8	30
347	Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. Journal of Clinical Investigation, 2021, 131, .	3.9	54
348	Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nature Reviews Cancer, 2021, 21, 145-161.	12.8	436
349	Adverse Effects of Biological Therapies on the Nervous System. , 2021, , 145-154.		0
350	COVID-19 in patients with cancer: Risks and precautions. American Journal of Emergency Medicine, 2021, 48, 357-360.	0.7	9
351	Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. OncoImmunology, 2021, 10, 1901434.	2.1	34
352	Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Stem Cell Investigation, 2021, 8, 1-1.	1.3	17
353	Genome editing of immune cells using CRISPR/Cas9. BMB Reports, 2021, 54, 59-69.	1.1	8
354	DAMPs released by pyroptotic cells as major contributors and therapeutic targets for CAR-T-related toxicities. Cell Death and Disease, 2021, 12, 129.	2.7	14
355	Therapeutic Strategies for Targeting IL-1 in Cancer. Cancers, 2021, 13, 477.	1.7	34
356	Nanomaterials for T-cell cancer immunotherapy. Nature Nanotechnology, 2021, 16, 25-36.	15.6	191

#	Article	IF	Citations
357	Blockade of AIM2 inflammasome or Î±1-AR ameliorates IL-1Î² release and macrophage-mediated immunosuppression induced by CAR-T treatment. , 2021, 9, e001466.		31
358	Preclinical development of CD126 CAR-T cells with broad antitumor activity. Blood Cancer Journal, 2021, 11, 3.	2.8	16
359	The Impact of Polyphenols-Based Diet on the Inflammatory Profile in COVID-19 Elderly and Obese Patients. Frontiers in Physiology, 2020, 11, 612268.	1.3	11
360	Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. Cell Transplantation, 2021, 30, 096368972199664.	1.2	22
361	Are all cytokine storms the same?. Cancer Immunology, Immunotherapy, 2021, 70, 887-892.	2.0	2
362	Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers, 2021, 13, 287.	1.7	61
363	The Many Faces of Cytokine Release Syndrome-Related Coagulopathy. Clinical Hematology International, 2021, 3, 3.	0.7	16
364	Novel highâ€affinity EGFRvIIIâ€specific chimeric antigen receptor T cells effectively eliminate human glioblastoma. Clinical and Translational Immunology, 2021, 10, e1283.	1.7	19
365	Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. Theranostics, 2021, 11, 8813-8835.	4.6	179
366	Hydrogels for Engineering the Immune System. Advanced NanoBiomed Research, 2021, 1, 2000073.	1.7	18
367	Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Frontiers in Immunology, 2021, 12, 611366.	2.2	41
368	Immune cartography of macrophage activation syndrome in the COVID-19 era. Nature Reviews Rheumatology, 2021, 17, 145-157.	3.5	75
369	VISTA: A Target to Manage the Innate Cytokine Storm. Frontiers in Immunology, 2020, 11, 595950.	2.2	24
370	Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy. Frontiers in Immunology, 2020, 11, 618387.	2.2	38
371	Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study. International Journal of Infectious Diseases, 2021, 103, 507-513.	1.5	25
373	How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. Journal of Clinical Oncology, 2021, 39, 456-466.	0.8	21
374	Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. Heliyon, 2021, 7, e06158.	1.4	40
375	Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement. Frontiers in Immunology, 2021, 12, 552429.	2.2	10

#	Article	IF	Citations
376	Hematologic changes predict clinical outcome in recovered patients with COVID-19. Annals of Hematology, 2021, 100, 675-689.	0.8	40
377	Engineering advanced logic and distributed computing in human CAR immune cells. Nature Communications, 2021, 12, 792.	5.8	68
378	CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial. Bone Marrow Transplantation, 2021, 56, 1642-1650.	1.3	14
379	Xenograft models for pediatric cancer therapies. Faculty Reviews, 2021, 10, 11.	1.7	2
380	Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells. HemaSphere, 2021, 5, e533.	1.2	8
381	Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. Frontiers in Immunology, 2020, 11, 569117.	2.2	26
382	Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia. Molecular Therapy, 2021, 29, 645-657.	3.7	39
383	Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide. Annals of Hematology, 2021, 100, 1295-1301.	0.8	2
384	Immediate Amelioration of Severe Respiratory Distress in SjÃ¶gren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab. Internal Medicine, 2021, 60, 639-643.	0.3	4
385	Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leukemia and Lymphoma, 2021, 62, 1765-1769.	0.6	25
386	Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction. Frontiers in Immunology, 2021, 12, 627764.	2.2	28
387	Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell, 2021, 184, 1575-1588.	13.5	111
388	Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy. Cellular Immunology, 2021, 361, 104277.	1.4	4
389	Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Diseases (Basel, Switzerland), 2021, 9, 20.	1.0	19
390	Monocytes and macrophages in COVID-19: Friends and foes. Life Sciences, 2021, 269, 119010.	2.0	97
391	Cytokine Release Syndrome Biology and Management. Cancer Journal (Sudbury, Mass), 2021, 27, 119-125.	1.0	25
392	Using Adoptive Cellular Therapy for Localized Protein Secretion. Cancer Journal (Sudbury, Mass), 2021, 27, 159-167.	1.0	3
393	Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?. Lancet Haematology,the, 2021, 8, e216-e228.	2.2	41

#	Article	IF	Citations
394	Profiles of Peripheral Immune Cells of Uncomplicated COVID-19 Cases with Distinct Viral RNA Shedding Periods. Viruses, 2021, 13, 514.	1.5	1
395	Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy. Journal of Immunology, 2021, 206, 1561-1568.	0.4	36
396	Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Communications Biology, 2021, 4, 368.	2.0	23
397	Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. Journal of Infection and Public Health, 2021, 14, 331-346.	1.9	12
398	Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview. Journal of Personalized Medicine, 2021, 11, 217.	1.1	17
399	Neurotoxicity Biology and Management. Cancer Journal (Sudbury, Mass), 2021, 27, 126-133.	1.0	7
400	Pharmacologic Control of CAR T Cells. International Journal of Molecular Sciences, 2021, 22, 4320.	1.8	9
401	Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. Frontiers in Pharmacology, 2021, 12, 650295.	1.6	23
402	The Association Between Glucocorticoid Administration and the Risk of Impaired Efficacy of Axicabtagene Ciloleucel Treatment: A Systematic Review. Frontiers in Immunology, 2021, 12, 646450.	2.2	10
403	CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy. Cell Discovery, 2021, 7, 27.	3.1	20
404	State-of-Art of Cellular Therapy for Acute Leukemia. International Journal of Molecular Sciences, 2021, 22, 4590.	1.8	12
405	Reactions Related to CAR-T Cell Therapy. Frontiers in Immunology, 2021, 12, 663201.	2.2	54
406	Strategies for Dodging the Obstacles in CAR T Cell Therapy. Frontiers in Oncology, 2021, 11, 627549.	1.3	35
407	The treatment of SARS-CoV2 with antivirals and mitigation of the cytokine storm syndrome: the role of gene expression. Genome, 2021, 64, 400-415.	0.9	0
408	Mechanisms of response and resistance to CAR T cell therapies. Current Opinion in Immunology, 2021, 69, 56-64.	2.4	18
409	Medical progress: Stem cells as a new therapeutic strategy for COVID-19. Stem Cell Research, 2021, 52, 102239.	0.3	9
410	Effect of physicochemical properties on inÂvivo fate of nanoparticle-based cancer immunotherapies. Acta Pharmaceutica Sinica B, 2021, 11, 886-902.	5.7	42
411	Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86â€“Positive B Cell Malignancies. Frontiers in Immunology, 2021, 12, 642528.	2.2	10

#	Article	IF	Citations
412	IL-6 modulation for COVID-19: the right patients at the right time?. , 2021, 9, e002285.		32
413	Overlapping and distinct biological effects of IL-6 classic and trans-signaling in vascular endothelial cells. American Journal of Physiology - Cell Physiology, 2021, 320, C554-C565.	2.1	15
414	Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. Future Oncology, 2021, 17, 1269-1283.	1.1	20
415	Current and emerging therapies for primary central nervous system lymphoma. Biomarker Research, 2021, 9, 32.	2.8	20
416	Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia. Medicine (United States), 2021, 100, e25786.	0.4	10
417	Neurological complications of cancer immunotherapy (CAR T cells). Journal of the Neurological Sciences, 2021, 424, 117405.	0.3	10
418	A positive feedback loop reinforces the allergic immune response in human peanut allergy. Journal of Experimental Medicine, 2021, 218, .	4.2	11
419	Chimeric Antigen Receptor T Cells for Glioblastoma. Neurology, 2021, 97, 218-230.	1.5	19
420	Immunological analysis of the murine antiâ€CD3â€induced cytokine release syndrome model and therapeutic efficacy of antiâ€cytokine antibodies. European Journal of Immunology, 2021, 51, 2074-2085.	1.6	11
421	Downregulation of Renal MRPs Transporters in Acute Lymphoblastic Leukemia Mediated by the IL-6/STAT3/PXR Signaling Pathway. Journal of Inflammation Research, 2021, Volume 14, 2239-2252.	1.6	5
423	CAR T-Cells for CNS Lymphoma: Driving into New Terrain?. Cancers, 2021, 13, 2503.	1.7	15
424	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circulation Research, 2021, 128, 1780-1801.	2.0	48
425	Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3725-3734.	1.2	59
426	Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient. International Journal of Hematology, 2021, 114, 408-412.	0.7	4
428	Therapeutic Potential of TNFÎ± and IL1Î² Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation. Frontiers in Immunology, 2021, 12, 623610.	2.2	21
429	Navigating CAR-T cells through the solid-tumour microenvironment. Nature Reviews Drug Discovery, 2021, 20, 531-550.	21.5	236
430	Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology, 2022, 22, 85-96.	10.6	315
431	Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?. Inflammation Research, 2021, 70, 651-663.	1.6	7

#	Article	IF	Citations
432	CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematology,the, 2021, 8, e446-e461.	2.2	75
433	CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e246-e265.	1.8	27
434	Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches. Journal of Medicinal Chemistry, 2021, 64, 9577-9591.	2.9	19
435	The â€œMagic Bulletâ€•Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells, 2021, 10, 1511.	1.8	3
436	TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy. JCI Insight, 2021, 6, .	2.3	6
437	Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. Advanced Drug Delivery Reviews, 2021, 173, 281-305.	6.6	38
438	Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. Leukemia and Lymphoma, 2021, 62, 2600-2611.	0.6	9
439	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. Frontiers in Immunology, 2021, 12, 693016.	2.2	45
440	Interleukins in cancer: from biology to therapy. Nature Reviews Cancer, 2021, 21, 481-499.	12.8	318
441	The potential of CAR T cell therapy for prostate cancer. Nature Reviews Urology, 2021, 18, 556-571.	1.9	25
442	Infusion reactions in natural killer cell immunotherapy: a retrospective review. Cytotherapy, 2021, 23, 627-634.	0.3	7
443	Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review. Frontiers in Immunology, 2021, 12, 693200.	2.2	8
444	Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective. Frontiers in Immunology, 2021, 12, 707191.	2.2	7
445	CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomedicine and Pharmacotherapy, 2021, 139, 111605.	2.5	92
446	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert Review of Anti-Infective Therapy, 2021, 19, 1219-1244.	2.0	6
447	Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. , 2021, 9, e002582.		14
448	Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Biomarker Research, 2021, 9, 58.	2.8	22
449	Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. Experimental and Molecular Medicine, 2021, 53, 1116-1123.	3.2	116

#	Article	IF	Citations
450	EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations. Neuro-Oncology, 2022, 24, 313-325.	0.6	16
451	Clonal hematopoiesis and its emerging effects on cellular therapies. Leukemia, 2021, 35, 2752-2758.	3.3	21
452	Chimeric antigen receptor Tâ€'cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. Voprosy Onkologii, 2021, 67, 350-360.	0.1	2
453	Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment. International Journal of Molecular Sciences, 2021, 22, 7652.	1.8	33
454	Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience. Journal of Pharmacy Practice, 2021, , 089719002110282.	0.5	1
455	CRP and ferritin in addition to the EASIX score predict CAR-Tâ€"related toxicity. Blood Advances, 2021, 5, 2799-2806.	2.5	57
456	Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer Journal, 2021, 11, 131.	2.8	28
457	Toxicities associated with adoptive cellular therapies. Best Practice and Research in Clinical Haematology, 2021, 34, 101287.	0.7	9
458	Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma. Journal of Blood Medicine, 2021, Volume 12, 775-783.	0.7	12
459	Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies. Blood Reviews, 2022, 51, 100883.	2.8	6
460	New CARs on and off the road: challenges and new developments in CAR-T cell therapy. Current Opinion in Pharmacology, 2021, 59, 116-126.	1.7	2
462	Can preclinical drug development help to predict adverse events in clinical trials?. Drug Discovery Today, 2022, 27, 257-268.	3.2	11
464	Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Research and Therapy, 2021, 12, 465.	2.4	69
465	The â€˜cytokine stormâ€™: molecular mechanisms and therapeutic prospects. Trends in Immunology, 2021, 42, 681-705.	2.9	156
466	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Advances, 2021, 5, 3397-3406.	2.5	59
467	Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood Cancer Journal, 2021, 11, 144.	2.8	18
468	The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?. Cytokine, 2021, 144, 155593.	1.4	61
469	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 2982-2986.	2.5	45

#	Article	IF	Citations
470	CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. Transplantation and Cellular Therapy, 2021, 27, 910.e1-910.e11.	0.6	26
471	CAR T cells: Building on the CD19 paradigm. European Journal of Immunology, 2021, 51, 2151-2163.	1.6	43
472	Interleukin-1 in tumor progression, therapy, and prevention. Cancer Cell, 2021, 39, 1023-1027.	7.7	47
473	Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nature Biomedical Engineering, 2021, 5, 1348-1359.	11.6	74
474	Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects. International Journal of Nanomedicine, 2021, Volume 16, 6017-6034.	3.3	10
475	Janus Kinase Inhibitors and Cell Therapy. Frontiers in Immunology, 2021, 12, 740847.	2.2	4
476	Monitoring and safety of CAR-T therapy in clinical practice. Expert Opinion on Drug Safety, 2022, 21, 363-371.	1.0	0
477	Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy. Cell Discovery, 2021, 7, 84.	3.1	16
478	Inflammaging, an Imbalanced Immune Response That Needs to Be Restored for Cancer Prevention and Treatment in the Elderly. Cells, 2021, 10, 2562.	1.8	13
479	Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches. Journal of Oncology Pharmacy Practice, 2022, 28, 107815522110392.	0.5	1
480	Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system. Leukemia and Lymphoma, 2021, , 1-9.	0.6	5
481	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 4465-4475.	2.5	28
482	State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. Transplantation and Cellular Therapy, 2021, 27, 973-987.	0.6	25
483	Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis. Cell Death and Differentiation, 2022, 29, 420-438.	5.0	14
484	Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a037820.	2.9	9
485	How I treat neurologic complications in patients with lymphoid cancer. Blood, 2022, 139, 1469-1478.	0.6	2
486	CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies. Cancers, 2021, 13, 4596.	1.7	1
487	SARS-CoV-2 and the Eye: The Pandora's Box of Ocular Immunology. Journal of Ocular Pharmacology and Therapeutics, 2021, 37, 502-509.	0.6	8

#	Article	IF	Citations
488	Immunological predictors of disease severity in patients with COVID-19. International Journal of Infectious Diseases, 2021, 110, 83-92.	1.5	12
489	Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. Molecular Cancer, 2021, 20, 5.	7.9	12
490	Cerebrospinal Fluid Biomarkers in Childhood Leukemias. Cancers, 2021, 13, 438.	1.7	4
491	The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. Translational Psychiatry, 2021, 11, 58.	2.4	36
492	Chimeric Antigen Receptor (CAR) Redirected T Cells. Learning Materials in Biosciences, 2021, , 251-302.	0.2	1
493	Emerging CAR landscape for cancer immunotherapy. Biochemical Pharmacology, 2020, 178, 114051.	2.0	6
494	Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 632-636.e1.	0.2	31
495	Cytokine IL-36Î³ improves CAR T-cell functionality and induces endogenous antitumor response. Leukemia, 2021, 35, 506-521.	3.3	31
496	STING agonist promotes CAR T cell trafficking and persistence in breast cancer. Journal of Experimental Medicine, 2021, 218, .	4.2	84
502	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
503	Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight, 2020, 5, .	2.3	51
504	B cell maturation antigenâ€“specific CAR T cells are clinically active in multiple myeloma. Journal of Clinical Investigation, 2019, 129, 2210-2221.	3.9	513
505	State of the art in CAR T cell therapy for CD19+ B cell malignancies. Journal of Clinical Investigation, 2020, 130, 1586-1594.	3.9	74
506	Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. Journal of Clinical Investigation, 2020, 130, 5425-5443.	3.9	37
507	Anticancer Drugs and the Nervous System. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 732-764.	0.4	13
508	Clinical outcomes and inflammatory marker levels in patients with Covid-19 and obesity at an inner-city safety net hospital. PLoS ONE, 2020, 15, e0243888.	1.1	16
509	CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGISTâ€™S THOUGHTS. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 123-132.	0.2	43
510	The role of interleukinâ€6 in monitoring severe case of coronavirus disease 2019. EMBO Molecular Medicine, 2020, 12, e12421.	3.3	293

#	Article	IF	Citations
511	Immunopharmacological aspects of the cytokine system. Bulletin of Siberian Medicine, 2019, 18, 84-95.	0.1	12
512	Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. Therapeutics and Clinical Risk Management, 2020, 16, 705-714.	0.9	40
513	Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives. Frontiers in Bioscience - Landmark, 2019, 24, 1284-1315.	3.0	12
514	Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia. Clinical Hematology International, 2019, 1, 85-93.	0.7	12
515	CART Cell Toxicities: New Insight into Mechanisms and Management. Clinical Hematology International, 2020, 2, 149.	0.7	19
516	Triggers, Timescales, and Treatments for Cytokine-Mediated Tissue Damage. European Medical Journal Innovations, 2021, 5, 52-62.	2.0	4
517	Cytokines in CAR T Cellâ€“Associated Neurotoxicity. Frontiers in Immunology, 2020, 11, 577027.	2.2	110
518	The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities. Cancers, 2021, 13, 38.	1.7	17
519	Interleukinâ€'6 signaling blockade treatment for cytokine release syndrome in COVIDâ€'19 (Review). Experimental and Therapeutic Medicine, 2020, 21, 1-1.	0.8	17
520	Dual specific CD19/CD22â€'targeted chimeric antigen receptor Tâ€'cell therapy for refractory diffuse large Bâ€'cell lymphoma: A case report. Oncology Letters, 2020, 20, 21.	0.8	7
521	Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	4
522	Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Frontiers in Immunology, 2021, 12, 745320.	2.2	41
523	Critical care management of chimeric antigen receptor Tâ€cell therapy recipients. Ca-A Cancer Journal for Clinicians, 2022, 72, 78-93.	157.7	29
524	Multimodular Optimization of Chemically Regulated T Cell Switches Demonstrates Flexible and Interchangeable Nature of Immune Cell Signaling Domains. Human Gene Therapy, 2021, 32, 1029-1043.	1.4	2
525	CAR T-cell therapy and critical care. Wiener Klinische Wochenschrift, 2021, 133, 1318-1325.	1.0	18
526	Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduction and Targeted Therapy, 2021, 6, 367.	7.1	31
527	Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults. Pediatric Hematology and Oncology, 2022, 39, 370-378.	0.3	6
528	Depletion of T cells via Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B. Frontiers in Immunology, 2021, 12, 734246.	2.2	15

#	Article	IF	Citations
529	Targeting folate receptor beta on monocytes/macrophages renders rapid inflammation resolution independent of root causes. Cell Reports Medicine, 2021, 2, 100422.	3.3	7
530	Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Advances, 2021, 5, 5344-5348.	2.5	16
531	Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens. Scientific Reports, 2021, 11, 19794.	1.6	6
532	The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. International Reviews of Immunology, 2022, 41, 649-668.	1.5	7
533	Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors. Frontiers in Immunology, 2021, 12, 738456.	2.2	6
534	Preclinical pharmacology modeling of chimeric antigen receptor T therapies. Current Opinion in Pharmacology, 2021, 61, 49-61.	1.7	11
535	From Aminopterin to Tisagenlecleucel: Childhood Acute Lymphoblastic Leukemia at the Forefront of Cancer Breakthroughs. , 2019, 16, .		0
536	Principles of Immuno-Oncology. , 2019, , 113-120.		0
537	Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care. , 2020, , 2035-2047.		0
538	Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors. Methods in Molecular Biology, 2020, 2086, 251-271.	0.4	2
539	CAR-T cell therapy for Acute Lymphoblastic Leukemia. Journal of Hematopoietic Cell Transplantation, 2020, 9, 93-99.	0.1	0
542	SÃndrome de neurotoxicidad asociada a cÃ©lulas inmunoefectoras: un enfoque terapÃ©utico en el paciente crÃtico. Medicina Intensiva, 2022, 46, 201-212.	0.4	2
543	Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours. Cells, 2021, 10, 2940.	1.8	5
544	Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward. Frontiers in Immunology, 2021, 12, 765097.	2.2	20
545	Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma. Cancers, 2021, 13, 5367.	1.7	10
546	Inflammatory Biomarkers and Neurotransmitter Perturbations in Delirium. , 2020, , 135-167.		0
547	Construction of PD1/CD28 Fusion Receptor Enhances Anti-Tumor Ability of c-Met CAR-T in Gastric Cancer. SSRN Electronic Journal, 0, , .	0.4	0
548	Acetylsalicylic acid of Eichengrin-Hoffmann, inflammatory mediators and issues of therapy of the initial stage of coronavirus infection COVID-19. Profilakticheskaya Meditsina, 2020, 123, 83.	0.2	1

#	Article	IF	Citations
549	Neurological Toxicities of Immunotherapy. , 2020, , 223-242.		0
550	GM-CSF: Master regulator of the T cell-phagocyte interface during inflammation. Seminars in Immunology, 2021, 54, 101518.	2.7	25
551	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. Gene Reports, 2021, 25, 101417.	0.4	15
552	Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences. Journal of Clinical Medicine, 2021, 10, 5190.	1.0	21
553	Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse. Frontiers in Oncology, 2021, 11, 750218.	1.3	12
554	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. Expert Review of Anticancer Therapy, 2021, 21, 1333-1353.	1.1	9
555	Cluster of differentiation 19 chimeric antigen receptor Tâ€'cell therapy in pediatric acute lymphoblastic leukemia (Review). Oncology Letters, 2020, 20, 36.	0.8	2
556	Prediction of Effective Cytokines in CAR-T Therapy with Semi- Supervised GCN. , 2020, , .		0
557	Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy. Oncotarget, 2020, 11, 3571-3581.	0.8	4
558	A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy. Aging, 2020, 12, 18741-18753.	1.4	19
559	A Review on Hematologic Malignant Patients Infected with 2019 Novel Coronavirus. Archives of Clinical Infectious Diseases, 2020, 15, .	0.1	0
561	Humanized mouse model: a review on preclinical applications for cancer immunotherapy. American Journal of Cancer Research, 2020, 10, 4568-4584.	1.4	13
562	Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomedicine and Pharmacotherapy, 2022, 145, 112419.	2.5	34
563	The Roles of Neutrophils in Cytokine Storms. Viruses, 2021, 13, 2318.	1.5	27
564	CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achillesâ€™ Heel?. Frontiers in Immunology, 2021, 12, 766220.	2.2	4
565	CARâ€Tâ€OPENIA: Chimeric antigen receptor Tâ€cell therapyâ€associated cytopenias. EJHaem, 2022, 3, 32-38.	0.4	16
566	Potential Applications and Perspectives of Humanized Mouse Models. Annual Review of Animal Biosciences, 2022, 10, 395-417.	3.6	18
567	Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11â€“13 2019, Verona, Italy. Cancer Immunology, Immunotherapy, 2021, , 1.	2.0	0

#	Article	IF	Citations
568	Pathogenesis and Treatment of Cytokine Storm Induced by Infectious Diseases. International Journal of Molecular Sciences, 2021, 22, 13009.	1.8	34
569	Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. International Journal of Molecular Sciences, 2021, 22, 12126.	1.8	8
571	Cancer immunotherapy: Challenges and limitations. Pathology Research and Practice, 2022, 229, 153723.	1.0	53
572	TCR-independent Activation in Presence of a Src-family Kinase Inhibitor Improves CAR-T Cell Product Attributes. Journal of Immunotherapy, 2021, Publish Ahead of Print, .	1.2	0
573	T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. Frontiers in Immunology, 2021, 12, 780442.	2.2	42
574	Multimodal Identification by Transcriptomics and Multiscale Bioassays of Active Components in Xuanfeibaidu Formula to Suppress Macrophage-Mediated Immune Response. Engineering, 2023, 20, 63-76.	3.2	10
575	Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncology, 2022, 18, 277-289.	1.1	20
576	Terapia con linfocitos T con receptor de antÃgeno quimÃ©rico (CAR-T) en pacientes con linfoma de cÃ©lula B agresivo. Perspectiva actual tras una dÃ©cada de tratamiento. Medicina ClÃnica, 2021, , .	0.3	0
577	Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology. Cancers, 2021, 13, 6052.	1.7	15
580	Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). , 2022, 10, e003847.		44
582	Therapeutic potential of CAR T cell in malignancies: A scoping review. Biomedicine and Pharmacotherapy, 2022, 146, 112512.	2.5	56
583	Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy. Journal of Controlled Release, 2022, 342, 210-227.	4.8	16
584	A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma. Current Research in Translational Medicine, 2022, 70, 103331.	1.2	5
586	CAR-T cell: Toxicities issues: Mechanisms and clinical management. Bulletin Du Cancer, 2021, 108, S117-S127.	0.6	7
587	Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma. Frontiers in Genetics, 2021, 12, 815679.	1.1	4
588	Autoimmune and Inflammatory Encephalopathies as Complications of Cancer. , 2022, , 430-459.		0
589	Infection complications in febrile chimeric antigen receptor (CAR)â€T recipients during the periâ€CARâ€T cell treatment period examined using metagenomic nextâ€generation sequencing (mNGS). Cancer Communications, 2022, 42, 476-480.	3.7	15
590	Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention. Journal of Oncology, 2022, 2022, 1-12.	0.6	1

#	Article	IF	Citations
591	JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. , 2022, 10, e003766.		15
592	Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Advances, 2022, 6, 1941-1946.	2.5	21
593	Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. Journal of Clinical Medicine, 2022, 11, 623.	1.0	20
594	CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report. Frontiers in Immunology, 2022, 13, 778192.	2.2	6
595	Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. Biomedicines, 2022, 10, 307.	1.4	9
597	Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina (Lithuania), 2022, 58, 144.	0.8	126
598	A Hot Topic: Cancer Immunotherapy and Natural Killer Cells. International Journal of Molecular Sciences, 2022, 23, 797.	1.8	6
599	IL-6/IFN-Î³ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro. Human Vaccines and Immunotherapeutics, 2022, 18, 1-14.	1.4	12
600	Strategies to overcome the side effects of chimeric antigen receptor T cell therapy. Annals of the New York Academy of Sciences, 2022, 1510, 18-35.	1.8	3
601	IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. Annual Review of Immunology, 2022, 40, 323-348.	9.5	50
603	In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy. Frontiers in Oncology, 2022, 12, 809754.	1.3	24
604	Management of haemostatic complications of chimaeric antigen receptor Tâ€cell therapy. British Journal of Haematology, 2022, 197, 250-259.	1.2	0
605	Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?. Nature Reviews Neurology, 2022, 18, 173-185.	4.9	31
606	Antiâ€CD19 and antiâ€BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stemâ€cell transplantation for highâ€risk newly diagnosed multiple myeloma. American Journal of Hematology, 2022, 97, 537-547.	2.0	23
607	A human orthogonal IL-2 and IL-2RÎ² system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Science Translational Medicine, 2021, 13, eabg6986.	5.8	64
608	Managing therapy-associated neurotoxicity in children with ALL. Hematology American Society of Hematology Education Program, 2021, 2021, 376-383.	0.9	4
609	Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. European Journal of Inflammation, 2022, 20, 1721727X2210787.	0.2	0
610	Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer. Antibody Therapeutics, 2022, 5, 73-83.	1.2	5

#	Article	IF	Citations
611	Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. OncoImmunology, 2022, 11, 2039432.	2.1	14
612	Role of Distinct Macrophage Populations in the Development of Heart Failure in Macrophage Activation Syndrome. International Journal of Molecular Sciences, 2022, 23, 2433.	1.8	3
613	CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma. Frontiers in Immunology, 2022, 13, 837457.	2.2	9
614	Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill. Medicina Intensiva (English Edition), 2022, , .	0.1	2
615	Immunotherapy Associated Neurotoxicity in Pediatric Oncology. Frontiers in Oncology, 2022, 12, 836452.	1.3	5
616	When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies. Frontiers in Oncology, 2022, 12, 837995.	1.3	2
617	Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. Frontiers in Oncology, 2022, 12, 841117.	1.3	9
618	A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021. Frontiers in Immunology, 2022, 13, 840956.	2.2	30
619	CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. Cytotherapy, 2022, 24, 841-849.	0.3	12
620	Largeâ€cohort humanized NPI mice reconstituted with CD34 ⁺ hematopoietic stem cells are feasible for evaluating preclinical cancer immunotherapy. FASEB Journal, 2022, 36, e22244.	0.2	4
621	Diminished durability of <scp>chimeric antigen receptor</scp> Tâ€cell efficacy with severe or prolonged <scp>postinfusion</scp> cytopenias. American Journal of Hematology, 2022, 97, .	2.0	1
622	Computational Analysis of Cytokine Release Following Bispecific T-Cell Engager Therapy: Applications of a Logic-Based Model. Frontiers in Oncology, 2022, 12, 818641.	1.3	4
624	IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nature Immunology, 2022, 23, 532-542.	7.0	178
625	Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models. International Journal of Molecular Sciences, 2022, 23, 3154.	1.8	15
626	Monocyte NLRP3â€Lâ€1Î² Hyperactivation Mediates Neuronal and Synaptic Dysfunction in Perioperative Neurocognitive Disorder. Advanced Science, 2022, 9, e2104106.	5.6	5
627	Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment. Medicina ClÃnica (English Edition), 2022, , .	0.1	0
628	<scp>CARâ€T</scp> cell therapy for lung cancer: Potential and perspective. Thoracic Cancer, 2022, 13, 889-899.	0.8	25
629	Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage. Cancers, 2022, 14, 1540.	1.7	11

#	Article	IF	Citations
630	Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2022, 63, 1566-1579.	0.6	11
631	Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism. Journal of Molecular Medicine, 2022, 100, 613-627.	1.7	5
632	Nanodiamond as a Cytokine Sponge in Infectious Diseases. Frontiers in Bioengineering and Biotechnology, 2022, 10, 862495.	2.0	6
633	Clinical Significance of Haplo-Fever and Cytokine Profiling After Graft Infusion in Allogeneic Stem Cell Transplantation From Haplo-Identical Donors. Frontiers in Medicine, 2022, 9, 820591.	1.2	2
634	Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, 305.e1-305.e9.	0.6	14
635	Anakinra utilization in refractory pediatric CAR T-cell associated toxicities. Blood Advances, 2022, 6, 3398-3403.	2.5	17
636	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 387-405.	2.3	124
637	Interleukin-1 (IL-1) and the inflammasome in cancer. Cytokine, 2022, 153, 155850.	1.4	30
638	Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells. Cancer Letters, 2022, 536, 215668.	3.2	11
639	Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. Journal of Experimental and Clinical Cancer Research, 2021, 40, 367.	3.5	72
640	Screening of Microbial Natural Products and Biological Evaluation of Trichomicin as Potential Anti-Cytokine Storm Agents. Frontiers in Pharmacology, 2021, 12, 770910.	1.6	2
641	Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cellular and Molecular Life Sciences, 2022, 79, 14.	2.4	27
643	Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapy. Brain Communications, 2022, 4, fcab309.	1.5	8
644	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. Frontiers of Medicine, 2021, 15, 783-804.	1.5	3
645	Blockade or Deletion of IFNÎ³ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies. Blood Cancer Discovery, 2022, 3, 136-153.	2.6	46
646	Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia. Cancers, 2021, 13, 6157.	1.7	12
647	Chimeric Antigen Receptor T Cells, the Shock of the New*. Critical Care Medicine, 2022, 50, 157-160.	0.4	0
648	Potential Role of IFNÎ³ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. Blood Cancer Discovery, 2022, 3, 90-94.	2.6	23

#	Article	IF	Citations
649	Immunotherapies and their moderation. , 2022, , 461-502.		0
650	Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer. Journal of the National Cancer Institute, 2022, 114, 930-939.	3.0	10
651	Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma. Clinical Cancer Research, 2022, 28, 2830-2843.	3.2	39
652	Chimeric anti-GPC3 sFv-CD3Îµ receptor-modified T cells with IL7 co-expression for the treatment of solid tumors. Molecular Therapy - Oncolytics, 2022, 25, 160-173.	2.0	4
653	Liposomal Dexamethasone Reduces A/H1N1 Influenza-Associated Morbidity in Mice. Frontiers in Microbiology, 2022, 13, 845795.	1.5	4
654	Review: Neurological Complications From Therapies for Pediatric Brain Tumors. Frontiers in Oncology, 2022, 12, 853034.	1.3	5
655	HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Advances, 2023, 7, 744-755.	2.5	5
656	Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduction and Targeted Therapy, 2022, 7, 101.	7.1	15
657	Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?. Bulletin of the National Research Centre, 2022, 46, 100.	0.7	2
665	CARâ€T cell therapy in paediatric acute lymphoblastic leukaemia â€“ past, present and future. British Journal of Haematology, 2020, 191, 617-626.	1.2	5
667	The Inflammatory Response to Craniocerebral Injury. Advances in Clinical Medicine, 2022, 12, 3500-3505.	0.0	0
668	Development of Cancer Immunotherapies. Cancer Treatment and Research, 2022, 183, 1-48.	0.2	4
669	Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. Cancer Treatment and Research, 2022, 183, 161-184.	0.2	2
671	Sepsis-associated brain injury: underlying mechanisms and potential therapeutic strategies for acute and long-term cognitive impairments. Journal of Neuroinflammation, 2022, 19, 101.	3.1	31
672	Type I interferon regulates proteolysis by macrophages to prevent immunopathology following viral infection. PLoS Pathogens, 2022, 18, e1010471.	2.1	5
673	A novel adoptive synthetic <scp>TCR</scp> and antigen receptor (<scp>STAR</scp>) <scp>Tâ€Cell</scp> therapy for <scp>Bâ€Cell</scp> acute lymphoblastic leukemia. American Journal of Hematology, 2022, 97, 992-1004.	2.0	8
674	CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. Journal of Clinical Investigation, 2022, 132, .	3.9	66
675	The IL-1 family in tumorigenesis and antitumor immunity. Seminars in Cancer Biology, 2022, 86, 280-295.	4.3	22

#	Article	IF	Citations
676	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
677	Time 2EVOLVE: predicting efficacy of engineered T-cells â€“ how far is the bench from the bedside?. , 2022, 10, e003487.		13
678	Clonal hematopoiesis: Mutation-specific adaptation to environmental change. Cell Stem Cell, 2022, 29, 882-904.	5.2	34
679	Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. OncoImmunology, 2022, 11, .	2.1	15
680	Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies. Transfusion and Apheresis Science, 2022, 61, 103473.	0.5	1
681	CAR-T cell therapies for cancer: what novel technologies are being developed for toxicity data?. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 241-244.	1.5	0
682	CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Frontiers in Immunology, 0, 13, .	2.2	55
683	Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy. Current Cardiology Reviews, 2022, 18, .	0.6	1
684	Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation. International Journal of Hematology, 2022, 116, 315-329.	0.7	3
685	CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity. International Journal of Molecular Sciences, 2022, 23, 6931.	1.8	3
686	Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia. Frontiers in Immunology, 0, 13, .	2.2	4
687	InÂvivo generation of CAR T cells in the presence of human myeloid cells. Molecular Therapy - Methods and Clinical Development, 2022, 26, 144-156.	1.8	8
688	Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers. , 2022, , 245-281.		0
689	NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. , 2022, 10, e003811.		26
690	Importance of CAR-T cell therapy monitoring using high-throughput assays. Drug Discovery Today, 2022, 27, 103310.	3.2	3
691	Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	4
692	Case Report: Clinical and Serological Hallmarks of Cytokine Release Syndrome in a Canine B Cell Lymphoma Patient Treated With Autologous CAR-T Cells. Frontiers in Veterinary Science, 0, 9, .	0.9	4
694	PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma. Cancer Research, 2022, 82, 3307-3320.	0.4	3

#	Article	IF	Citations
695	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cellâ€“Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. Clinical Cancer Research, 2022, 28, 3804-3813.	3.2	17
696	Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma. Expert Review of Anticancer Therapy, 2022, 22, 903-914.	1.1	1
697	Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational study. Sao Paulo Medical Journal, 0, , .	0.4	1
698	The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation. Leukemia and Lymphoma, 0, , 1-7.	0.6	0
699	Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy. Diseases (Basel, Switzerland), 2022, 10, 41.	1.0	6
700	Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation, 2022, 57, 1477-1488.	1.3	28
701	Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. Frontiers in Immunology, 0, 13, .	2.2	4
702	Mechanisms of immune effector <scp>cellâ€associated</scp> neurotoxicity syndrome after <scp>CARâ€T</scp> treatment. WIREs Mechanisms of Disease, 2022, 14, .	1.5	5
703	Preclinical In Vitro and In Vivo Models for Adoptive Cell Therapy of Cancer. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.0	2
704	Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment. International Journal of Molecular Sciences, 2022, 23, 8242.	1.8	4
705	Neurologic adverse events of cancer immunotherapy. Arquivos De Neuro-Psiquiatria, 2022, 80, 270-280.	0.3	1
706	The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook. Frontiers in Immunology, 0, 13, .	2.2	2
708	Prognosis of systemic inflammation at an early stage of cirrhosis using the monocyte-to-lymphocyte ratio during malnutrition risk screening: a prospective cohort study. Postgraduate Medicine, 2022, 134, 801-809.	0.9	1
709	Understanding CAR TÂcell-tumor interactions: Paving the way for successful clinical outcomes. Med, 2022, 3, 538-564.	2.2	11
710	Secretory co-factors in next-generation cellular therapies for cancer. Frontiers in Immunology, 0, 13, .	2.2	1
711	A Computational Model of Cytokine Release Syndrome during CAR Tâ€Cell Therapy. Advanced Therapeutics, 2022, 5, .	1.6	1
713	Adverse Renal Effects of Anticancer Immunotherapy: A Review. Cancers, 2022, 14, 4086.	1.7	3
714	CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives. Biomedicines, 2022, 10, 1960.	1.4	5

#	Article	IF	Citations
716	Application of nanotechnology in CAR-T-cell immunotherapy. Chinese Chemical Letters, 2023, 34, 107747.	4.8	5
717	Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy. Haematologica, 2023, 108, 444-456.	1.7	5
718	Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Frontiers in Immunology, 0, 13, .	2.2	20
719	Combined IFN-Î³ and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice. Journal of Allergy and Clinical Immunology, 2023, 151, 247-259.e7.	1.5	9
720	Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study. Antibiotics, 2022, 11, 1078.	1.5	1
721	Cancer-associated fibroblast-like fibroblasts in vocal fold leukoplakia suppress CD8+T cell functions by inducing IL-6 autocrine loop and interacting with Th17 cells. Cancer Letters, 2022, 546, 215839.	3.2	12
722	Applying a clinical lens to animal models of CAR-T cell therapies. Molecular Therapy - Methods and Clinical Development, 2022, 27, 17-31.	1.8	18
723	Orthotopic PDX and CDX Mice Model for Cancer Stem Cell Research. , 2022, , 1-24.		0
724	Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy. Journal of Materials Chemistry B, 2022, 10, 7491-7511.	2.9	8
725	Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies. , 2022, , 111-173.		0
726	Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy. Frontiers in Immunology, 0, 13, .	2.2	4
727	CD55 Facilitates Immune Evasion by Borrelia crocidurae, an Agent of Relapsing Fever. MBio, 2022, 13, .	1.8	2
729	Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access. JCO Oncology Practice, 2022, 18, 800-807.	1.4	29
730	Transcriptional states of CAR-T infusion relate to neurotoxicity â€“ lessons from high-resolution single-cell SOM expression portraying. Frontiers in Immunology, 0, 13, .	2.2	4
731	CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nature Communications, 2022, 13, .	5.8	35
732	CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies. Frontiers in Immunology, 0, 13, .	2.2	10
733	Transmembrane TNF-Î± as a Novel Biomarker for the Diagnosis of Cytokine Storms in a Mouse Model of Multiple Organ Failure. Inflammation, 2023, 46, 359-369.	1.7	1
734	Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nature Medicine, 2022, 28, 1860-1871.	15.2	80

#	Article	IF	Citations
735	Cardiovascular disease and chimeric antigen receptor cellular therapy. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
736	Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors. Biomolecules, 2022, 12, 1239.	1.8	4
737	BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. Cancer Letters, 2023, 553, 215949.	3.2	11
738	Cytokine release syndrome after CAR T-cell therapy: a review of the literature and our experience. Anesteziologie A Intenzivni Medicina, 2022, 33, 90-96.	0.1	0
739	Whole-process management of complications during CAR-T therapy. , 2022, 1, .		0
740	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	6.9	59
741	Tumor buster - where will the CAR-T cell therapy â€˜missileâ€™ go?. Molecular Cancer, 2022, 21, .	7.9	23
742	Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors. Cancers, 2022, 14, 5108.	1.7	9
743	The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Frontiers in Pharmacology, 0, 13, .	1.6	7
744	Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma. Experimental Hematology and Oncology, 2022, 11, .	2.0	9
745	Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH). EMBO Molecular Medicine, 2022, 14, .	3.3	7
747	Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer Journal, 2022, 12, .	2.8	19
748	Toxicities following CAR-T therapy for hematological malignancies. Cancer Treatment Reviews, 2022, 111, 102479.	3.4	13
749	CAR T Cell Immunotherapy That Revolutionary Breakthrough in Human Oncology Treatment: A Review. Pharmacology & Pharmacy, 2022, 13, 483-515.	0.2	0
751	Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics. Drug Discovery Today, 2022, , 103440.	3.2	1
752	PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models. Cellular Oncology (Dordrecht), 2023, 46, 227-235.	2.1	7
753	Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development. Frontiers in Immunology, 0, 13, .	2.2	2
754	CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. Frontiers in Immunology, 0, 13, .	2.2	24

#	Article	IF	Citations
755	The role of IL-6 in coronavirus, especially in COVID-19. Frontiers in Pharmacology, 0, 13, .	1.6	15
756	Cancer Immunotherapy Beyond Checkpoint Blockade. JACC: CardioOncology, 2022, 4, 563-578.	1.7	1
757	Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell, 2022, 40, 1470-1487.e7.	7.7	11
758	SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity. Scientific Reports, 2022, 12, .	1.6	4
759	Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors. Frontiers in Immunology, 0, 13, .	2.2	1
760	Cardiotoxicity of T-Cell AntineoplasticÂTherapies. JACC: CardioOncology, 2022, 4, 616-623.	1.7	10
762	Humanized mouse models for immuno-oncology research. Nature Reviews Clinical Oncology, 2023, 20, 192-206.	12.5	54
763	Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity. Frontiers in Immunology, 0, 13, .	2.2	3
765	Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Reports, 2023, 18, 585-596.	2.3	12
766	Molecular and therapeutic effect of CRISPR in treating cancer. , 2023, 40, .		2
767	CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. , 2023, 11, e005878.		11
768	Four challenges to CAR T cells breaking the glass ceiling. European Journal of Immunology, 2023, 53, .	1.6	10
770	PRECLINICAL MOUSE MODELS IN ADOPTIVE CELL THERAPIES OF CANCER. Slovenian Veterinary Research, 2022, 59, .	0.0	0
771	CAR T cells: engineered immune cells to treat brain cancers and beyond. Molecular Cancer, 2023, 22, .	7.9	7
772	Bright future or blind alley? CAR-T cell therapy for solid tumors. Frontiers in Immunology, 0, 14, .	2.2	10
773	CAR T-cell behavior and function revealed by real-time imaging. Seminars in Immunopathology, 2023, 45, 229-239.	2.8	6
774	Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPÎ± checkpoint blocker. Blood, 2023, 141, 2003-2015.	0.6	9
775	Orthotopic PDX and CDX Mice Model for Cancer Stem Cell Research. , 2023, , 503-526.		0

#	Article	IF	Citations
776	Advancing CAR T cell therapy through the use of multidimensional omics data. Nature Reviews Clinical Oncology, 2023, 20, 211-228.	12.5	30
777	A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma. Frontiers in Oncology, 0, 12, .	1.3	3
778	Possible role of IL-6 and IL-17 among COVID-19 patients. AIP Conference Proceedings, 2023, , .	0.3	0
779	The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression. Frontiers in Immunology, 0, 14, .	2.2	6
780	Anakinraâ€"An Interleukin-1 Receptor Antagonist for COVID-19. American Journal of Therapeutics, 2023, 30, e108-e116.	0.5	4
781	2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Biology and Medicine, 0, , 129-146.	1.4	0
782	CAR-T cells for cancer immunotherapy. Chinese Chemical Letters, 2023, 34, 108202.	4.8	3
783	The adrenal stress response is an essential host response against therapy-induced lethal immune activation. Science Signaling, 2023, 16, .	1.6	0
784	Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2023, 29, 430-437.	0.6	15
785	CAR T-cells to treat brain tumors. Brain Research Bulletin, 2023, 196, 76-98.	1.4	7
786	Therapeutic strategies targeting pro-fibrotic macrophages in interstitial lung disease. Biochemical Pharmacology, 2023, 211, 115501.	2.0	4
787	Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Cytotherapy, 2023, 25, 653-658.	0.3	3
788	Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches. Biomarker Research, 2023, 11, .	2.8	2
789	Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Expert Opinion on Drug Safety, 2023, 22, 5-15.	1.0	1
790	Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis. Cells, 2023, 12, 531.	1.8	1
791	Nanomodified Switch Induced Precise and Moderate Activation of CARâ€T Cells for Solid Tumors. Advanced Science, 2023, 10, .	5.6	2
792	A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. Frontiers in Neurology, 0, 14, .	1.1	4
793	Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	4

#	Article	IF	Citations
795	Inducible generalized activation of hSTING-N154S expression in mice leads to lethal hypercytokinemia: a model for â€œcytokine stormâ€• Journal of Leukocyte Biology, 2023, 113, 326-333.	1.5	0
796	Novel pathophysiological insights into CAR-T cell associated neurotoxicity. Frontiers in Neurology, 0, 14, .	1.1	4
797	CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacy. Leukemia and Lymphoma, 2023, 64, 808-815.	0.6	3
798	Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Blood Research, 2023, 58, S20-S28.	0.5	3
799	Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	19
800	CAR T-Cell Therapy in Children with Solid Tumors. Journal of Clinical Medicine, 2023, 12, 2326.	1.0	2
801	The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Frontiers in Immunology, 0, 14, .	2.2	23
802	Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. Cancers, 2023, 15, 1989.	1.7	2
803	RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines. Investigational New Drugs, 2023, 41, 220-225.	1.2	1
804	Progress in the study of molecular mechanisms of cell pyroptosis in tumor therapy. International Immunopharmacology, 2023, 118, 110143.	1.7	3
805	CAR T-Cell Therapy. , 2023, , 1042-1049.		0
806	CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?. Frontiers in Neurology, 0, 14, .	1.1	6
807	Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager. Frontiers in Immunology, 0, 14, .	2.2	2
808	A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. Frontiers in Immunology, 0, 14, .	2.2	4
809	Mouse models for immuno-oncology. Trends in Cancer, 2023, 9, 578-590.	3.8	2
819	Chimeric Antigen Receptor Therapy in Acute Myeloid Leukemia. , 2024, , 205-216.		0
829	CAR T-Cell Therapy and Critical Care Considerations. , 2023, , 427-435.		0
830	NK cells direct the perspective approaches to cancer immunotherapy. , 2023, 40, .		0

#	Article	IF	Citations
833	Impact of CAR-T cell therapy on treating viral infections: unlocking the door to recovery. Human Cell, 2023, 36, 1839-1842.	1.2	1
836	Interleukin-1-mediated immune suppression and resistance to immunotherapy in cancer. , 2023, , 87-98.		0
839	Neurologic Complications of Chimeric Antigen Receptor Therapy. , 2024, , 525-536.		0
840	Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy. , 2024, , 509-524.		0
841	Process and General Management of Patients Undergoing Chimeric Antigen Receptor Therapies. , 2024, , 115-122.		0
847	Advanced Therapy Medicinal Products. , 2023, , 1-25.		0
868	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5
874	Bioengineering translational models of lymphoid tissues. , 2023, 1, 731-748.		2
909	Taming CAR T cell therapy toxicity. Nature Materials, 2023, 22, 1444-1445.	13.3	0
916	Cytokine storm and translating IL-6 biology into effective treatments for COVID-19. Frontiers of Medicine, 2023, 17, 1080-1095.	1.5	0
917	Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond. Advances in Protein Chemistry and Structural Biology, 2024, , .	1.0	0
918	Cytokine storm in COVID-19 and other diseases: emerging therapeutic interventions. , 2024, , 209-241.		0
926	Anti-cytokine strategies targeting CAR-T cell therapy-induced cytokine release syndrome. , 2024, , .		0
935	The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. Annals of Hematology, 0, , .	0.8	0